Jeff Yass’s Genocea Biosciences, Inc. GNCA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-56,458
| Closed | -$129K | – | 12155 |
|
|
2020
Q3 | $129K | Sell |
56,458
-4,324
| -7% | -$11.3K | ﹤0.01% | 9788 |
|
|
2020
Q2 | $140K | Sell |
60,782
-3,526
| -5% | -$8.12K | ﹤0.01% | 9309 |
|
|
2020
Q1 | $111K | Buy |
+64,308
| New | +$130K | ﹤0.01% | 9252 |
|
|
2019
Q4 | – | Sell |
-42,354
| Closed | -$100K | – | 11262 |
|
|
2019
Q3 | $123K | Buy |
42,354
+24,932
| +143% | +$85.1K | ﹤0.01% | 9448 |
|
|
2019
Q2 | $68K | Buy |
17,422
+15,347
| +740% | +$80.1K | ﹤0.01% | 9758 |
|
|
2019
Q1 | $10K | Buy |
+2,075
| New | +$10.3K | ﹤0.01% | 8659 |
|
|
2018
Q2 | – | Sell |
-5,602
| Closed | -$47K | – | 10855 |
|
|
2018
Q1 | $47K | Buy |
5,602
+2,905
| +108% | +$24.1K | ﹤0.01% | 8973 |
|
|
2017
Q4 | $25K | Sell |
2,697
-2,833
| -51% | -$28.5K | ﹤0.01% | 9047 |
|
|
2017
Q3 | $65K | Buy |
+5,530
| New | +$210K | ﹤0.01% | 8486 |
|
|
2017
Q2 | – | Sell |
-5,557
| Closed | -$271K | – | 10202 |
|
|
2017
Q1 | $271K | Buy |
5,557
+3,149
| +131% | +$123K | ﹤0.01% | 7507 |
|
|
2016
Q4 | $79K | Buy |
+2,408
| New | +$79.3K | ﹤0.01% | 9171 |
|
|
2016
Q3 | – | Sell |
-6,503
| Closed | -$213K | – | 9382 |
|
|
2016
Q2 | $213K | Buy |
+6,503
| New | +$238K | ﹤0.01% | 7514 |
|
Other funds holding GNCA
Jeff Yass's GNCA Position: Q4 2020 in Review
Jeff Yass sold out of Genocea Biosciences, Inc. (GNCA) in Q4 2020, closing a stake of 56,458 shares — an estimated $129K sold.
Jeff Yass first reported a position in GNCA in Q2 2016 and held it in 12 quarters. The position peaked at $271K in Q1 2017. 39 funds tracked by Wall St. Rank hold GNCA as of Q4 2020.
- Jeff Yass reported no remaining Genocea Biosciences, Inc. position as of Q4 2020 after selling out during the quarter.
- Jeff Yass sold 56,458 Genocea Biosciences, Inc. shares in Q4 2020, an estimated $129K.
- Jeff Yass first reported a position in Genocea Biosciences, Inc. in Q2 2016 and held it in 12 quarters.
- Jeff Yass's Genocea Biosciences, Inc. position peaked at $271K in Q1 2017.
- 39 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q4 2020.
Based on Susquehanna International Group's 13F filing for Q4 2020, filed 16 Feb 2021.